Newsroom

Neuroscience

Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session

October 3, 2024

United States

Learn more

Oncology

ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer

October 2, 2024

Portugal

Learn more

Oncology

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

September 30, 2024

United States

Learn more

Oncology

CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

September 27, 2024

Brazil

Learn more

DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

September 27, 2024

Brazil

Learn more

Oncology

TALVEY^® (talquetamab-tgvs) and DARZALEX FASPRO^® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma

September 27, 2024

United States

Learn more

Oncology

Novel combination of TALVEY^® (talquetamab-tgvs) and TECVAYLI^® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

September 27, 2024

Learn more

Oncology

DARZALEX^® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma

September 20, 2024

Belgium

Learn more

Oncology

RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer

September 19, 2024

United States

Learn more

Oncology

Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer

TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence

September 16, 2024

Spain

Learn more

Newsroom

Press Releases